新易盛(300502.SZ):擬使用募集資金約13.32億元及其利息向四川新易盛增資
格隆匯 12 月 10日丨新易盛(300502.SZ)公佈,根據《新易盛2020年度創業板向特定對象發行股票募集説明書(註冊稿)》披露,此次募集資金投資項目的實施主體為公司全資子公司四川新易盛通信技術有限公司(“四川新易盛”)。為保證公司募集資金投資項目四川新易盛高速率光模塊生產線項目的順利實施,公司擬使用募集資金133176.26萬元及其利息向四川新易盛增資,此次增資是基於募投項目的實際運營需要而進行,有利於保證募集資金投資項目的順利實施,符合募集資金使用計劃,也符合公司及全體股東的利益。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.